Porcine hemagglutinating encephalomyelitis virus cDNA and Antigen

Porcine hemagglutinating encephalomyelitis virus (PHEV) is a type of virus that affects pigs and can cause encephalomyelitis, which is an inflammation of the brain and spinal cord. PHEV belongs to the family Coronaviridae and is a member of the Alphacoronavirus genus. The virus is spread through oral transmission and primarily affects pigs that are less than six months old. Symptoms of PHEV infection include ataxia, depression, and tremors. There is currently no specific treatment for PHEV infection, and control measures primarily focus on biosecurity and vaccination.

An antigen is a substance that triggers the production of antibodies in the immune system. Antigens can be proteins, sugars, or other molecules that are found on the surface of pathogens such as viruses. In the case of Porcine hemagglutinate encephalomyelitis virus (PHEV), the viral antigen can be used to develop a vaccine to protect pigs from PHEV infection. Vaccines work by introducing a harmless piece of the virus (such as an antigen) into the body, which triggers the immune system to produce antibodies against the virus. These antibodies will then recognize and neutralize the virus if it infects the animal in the future. The production of recombinant antigens for PHEV can be used to improve the efficacy of PHEV vaccines and reduce the impact of PHEV infections in pigs.

The genome of Porcine hemagglutinate encephalomyelitis virus (PHEV) is a strand of RNA that contains the genetic information necessary for the virus to replicate and infect cells. PHEV is a small, non-enveloped RNA virus that belongs to the Caliciviridae family. The genetic information encoded in the PHEV genome is used to produce viral proteins that are necessary for the virus to replicate, evade the host immune system, and cause disease. The study of the PHEV genome can provide important insights into the biology and pathogenesis of PHEV infections, which can help in the development of effective control strategies for PHEV outbreaks in pigs. The virus is composed of several structural and non-structural proteins, with the envelope protein, hemagglutinin-esterase protein, and nucleoprotein being key components.

The envelope protein is responsible for the virus’s structure and plays an important role in viral replication and entry into host cells.

The hemagglutinin-esterase protein is involved in the attachment of the virus to host cells and is essential for the virus’s ability to cause disease.

The nucleoprotein, on the other hand, is responsible for the virus’s genome packaging and replication.

Understanding the structure and function of these proteins is critical for developing effective prevention and treatment strategies for PHEV. Ongoing research is focused on identifying new targets for intervention and developing new approaches for controlling the spread of this disease in pig populations.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.